Shire licenses recombinant immunoglobulin from AB Biosciences
AB Biosciences Inc. (Allston, Mass.) granted Shire plc (LSE:SHP; NASDAQ:SHPG) exclusive, worldwide rights to develop and commercialize its pan receptor interacting molecule (PRIM) program. PRIM is a recombinant immunoglobulin that AB Biosciences said has shown...
